International Journal of Pharmaceutical and Bio-Medical Science

ISSN(print): 2767-827X, ISSN(online): 2767-830X

Volume 05 Issue 08 August 2025

Page No : 441-450

DOI: https://doi.org/10.47191/ijpbms/v5-i8-01, Impact Factor: 8.163

Cracking the Code of Rare Brain Diseases -A Clinical Insight on Progressive Multifocal Leukoencephlopathy

Bejjam Priscilla, Sree Sushumna*[1], Sridhar Siddiraju*[2]

[1]Pharm D, Malla Reddy College of Pharmacy (MRCP), Maisammaguda, Telangana, India -500100

[2]Department of Pharmaceutical Chemistry, Malla Reddy College of Pharmacy (MRCP), Maisammaguda, Telangana, India -500100

ABSTRACT

Rare diseases of the central nervous system (CNS) represent an enormous, yet frequently overlooked, health burden; this is particularly true in countries like India, where the agenda is predominantly dominated by infectious and lifestyle diseases. This largely stems from the fact that rare diseases are usually of genetic origin or neurodegenerative in nature where patients encounter diagnostic delays and treatment options are limited because of accessibility to specialized care. Progressive Multifocal Leukoencephalopathy (PML) is a rare demyelinating disorder which has been diagnosed more often in recent times and continues to be a health burden for many. *[1]

Progressive Multifocal Leukoencephalopathy (PML) represents a rare yet increasingly diagnosed condition which results from the JC virus reactivation in people with weakened immune systems. The immune system suppression caused by natalizumab and rituximab and fingolimod has led to the emergence of PML cases among patients despite its previous history of occurrence mainly in AIDS patients. In PML, JC virus reactivation leads to infection of oligodendrocytes, culminating in widespread demyelination which produces symptoms that include motor and visual impairments along with cognitive deterioration and ataxia. *[2]

Medical professionals diagnose the condition by analyzing MRI results along with JC virus DNA presence in cerebrospinal fluid. The main obstacle to early detection exists because PML symptoms resemble other CNS diseases. Currently, immune reconstitution remains the cornerstone of PML management by antiretroviral therapy for HIV patients and immunosuppressant withdrawal for others. This article establishes the urgent necessity to raise awareness about rare CNS diseases while promoting genetic testing alongside patient learning and healthcare policies that support these conditions. The research demonstrates how studying uncommon medical disorders contributes to expanding knowledge about neurological and immunological systems. *[3]

ARTICLE DETAILS

Published On:
04 August 2025

KEYWORDS: JC Virus, Natalizumab, Rituximab, Fingolimod, Oligodendrocytes, Demyelination, Ataxia

Available on:
https://ijpbms.com/

"The rarest diseases often carry the richest lessons" -Dr. Stephen Groft

1. INTRODUCTION

"When the World Forgets, Science Remembers…" In a world where medical headlines often revolve around the common cold or cancer, there lies a silent cry—millions affected by rare diseases, each with a name few can pronounce and even fewer understand. These are not just conditions; they're daily battles fought in the shadows. But change is stirring. With breakthrough therapies, genetic research, and global awareness campaigns, what was once considered untreatable is finally stepping into the light. This article takes you on a journey through the evolving landscape

of rare disease treatment—where hope meets science, and every cure begins with a question

In a country like India, where the focus of public health discussions is primarily on infectious diseases, malnourishment and lifestyle-related noninfectious diseases, rare diseases are a significant blind spot. These conditions, often unknown even to the general public are defined in developed nations as impacting a tiny proportion of the populace, which is fewer than 200,000 individuals in the U.S (as per NIH definition), and under 5 in every 10,000 in Europe. Without a standardized national definition, India is believed to home over 70 million people who are silently suffering from rare disorders, many of them involving the central nervous system (CNS)

Many rare CNS disorders exhibit familial inheritance, progressive clinical courses, and l.ong durations. They not only involve the brain and the spinal cord but also affect other systems of the body. It ranges from inherited leukodystrophies and autoimmune encephalitis to some littleknown neurodegenerative diseases in middle aged people. Patients having these diseases are often forced to endure long involuntary periods due to lack of specialized care which adds to their treatment costs alongside suffering emotionally due to psychologically unfit systems. Children suffering from these conditions grapple with convoluted treatment options that often lead them down paths of misdiagnosis. ***[1]**

The study of unusual diseases provides scientists with important keys to unlock more comprehensive scientific knowledge. The 17th century physician William Harvey explained that nature reveals her hidden workings most clearly through uncommon phenomena. The example of Progressive Multifocal Leukoencephalopathy (PML) demonstrates how rare neurological disorders function. The reactivation of JC virus in people with compromised immune systems demonstrates essential connections between virus biology and neurological and immunological science. The condition which was once considered uncommon now occurs more frequently because of HIV/AIDS infections and immunosuppressive medical treatments.

The article investigates unusual CNS disorders through their origins and manifestations and diagnostic methods and therapeutic approaches. The case of a multiple sclerosis patient who developed PML during natalizumab treatment demonstrates the intricate nature of diagnosis and the important need for clinical monitoring. Genetic screening combined with early detection systems and gene-based therapies are changing how patients fare. Although medical science has yet to find complete cures early treatment enhances patient quality of life. The healthcare system must combine research efforts with empathy and organized support structures to address rare diseases. *[2]

Progressive Multifocal Leukoencephalopathy (PML) emerges as a rapidly progressing demyelinating disease which mainly targets immunocompromised individuals according to its initial discovery in 1958 (Koralnik, 2006). The John Cunningham (JC) virus represents a common human polyomavirus which establishes latent infections in the kidneys and lymphoid tissue and possibly the brain. During periods of compromised cellular Immunity the virus becomes reactivated to breach the blood-brain barrier where it infects oligodendrocytes leading to extensive white matter damage through demyelination and cell death.

During the HIV/AIDS epidemic PML became a major clinical concern because it affected about 5% of AIDS patients before ART became available. Recent medical reports show an increasing number of cases of PML among patients who receive immunosuppressive or immunomodulatory treatments including natalizumab that doctors use to treat multiple sclerosis and Crohn's disease (White & Khalili, 2011; Tan & Koralnik, 2010). The rising occurrence of PML as an iatrogenic condition rather than a rare immune deficiency complication requires better clinical monitoring of patients at risk. *[4]

2. ETIOLOGY AND PATHOGENESIS

2.1 JC Virus Background-

The JC virus establishes a lifelong latent infection in the kidneys and lymphoid tissue and possibly the brain of 70-90% of adults worldwide (Du Pasquier & Koralnik, 2013). The virus reactivates only under exceptional circumstances when immune system cells become deficient (Tan & Koralnik, 2010).

2.2 Mechanism of CNS Infection-

During immunosuppression, JC virus may traverse the blood-brain barrier and infect oligodendrocytes which produce myelin in the CNS. The lytic infection of oligodendrocytes leads to myelin sheath destruction which produces the multifocal demyelination typical of PML (Hoang-Xuan et al., 1986; Major et al., 1992).



2.3 Risk Factors for Reactivation-

- HIV/AIDS: The lack of immunity triggers frequent JC virus reactivation while PML develops in up to 5% of AIDS patients who do not receive treatment (Wüthrich et al., 2012).
- Immunosuppressive therapies: The medications natalizumab and rituximab and fingolimod elevate PML risk by reducing immune system surveillance functions (Tan et al., 2013; Bloomgren et al., 2012; Clifford et al., 2011).
- Organ transplantation: The use of immunosuppressants after transplantation can trigger the onset of PML (Hoang-Xuan et al., 1998).
- Additional yet rare causes include congenital immunodeficiency (genetic disorders that impair immune system usually present at birth) and hematological malignancies (cancers originating from bone marrow and lymph nodes) (Richardson & Berger, 1998; D'Arcy et al., 2015)

Table 1: Key Risk Factors Associated with PML

Risk Factor	Relative Risk Increase	Comments
HIV/AIDS	High	Risk highest in untreated individuals; prevalence can reach up to 5% without antiretroviral therapy (ART).
Natalizumab (MS therapy)	Moderate to High	Risk increases with treatment duration and presence of anti-JCV antibodies.
Rituximab (for cancer/rheumatologic diseases)	Moderate	Documented PML cases especially in patients with lymphomas and autoimmune conditions.

Organ Transplantation	Moderate	Long-term immunosuppressive therapy contributes to increased susceptibility.
Hematologic Malignancies	Moderate	Associated with impaired immune regulation and lymphocyte depletion.

3. EPIDEMIOLOGY

Progressive Multifocal Leukoencephalopathy (PML) occurs at a rate between 0.2 and 4.4 cases per 100,000 person-years based on general population statistics but its incidence rises significantly in immunocompromised groups (Koralnik & Tyler, 2016). The primary occurrence of PML disease took place in AIDS patients during its early discovery because advanced or untreated HIV patients experienced about 5% disease development. Among the patients with HIV positive when treated with effective antiretroviral therapy (ART) resulted in substantial decrease of PML (Berger & Houff, 2006). The growing application of immunomodulatory and immunosuppressive treatments for autoimmune and hematological disorders has led to the emergence of new patient groups at risk. Patients who receive natalizumab for multiple sclerosis and rituximab for lymphomas and rheumatoid arthritis face higher chances of developing PML. The evolving situation demands enhanced risk evaluation alongside patient knowledge dissemination and continuous clinical surveillance of vulnerable populations (Ho & Tourbah, 2014).

4. CLINICAL PRESENTATION

Neurological Symptoms-

Clinical Presentation of Progressive Multifocal Leukoencephalopathy (PML):

- Onset: PML symptoms can progress rapidly if untreated. (Tan & Koralnik, 2010).
- Common Early Symptoms:
  - Motor Deficits: Unilateral weakness, hemiparesis (Tan & Koralnik, 2010)
  - Visual Disturbances: Visual field loss, cortical blindness (Koralnik & Wüthrich, 2007)
  - Cognitive Impairment: includes memory loss, dementia,confusion etc.(Marzocchetti et al., 2009)
  - Speech Difficulties: Dysarthria, aphasia (Cinque et al., 2003)
  - Ataxia: Gait imbalance, coordination problems (Cortese, Reich & Nath, 2021)
- Disease Progression: PML symptoms can progress rapidly if untreated. Tremendous deterioration can occur in a matter of weeks and can lead to severe disability or even death (Berger et al., 2013).
- Timely diagnosis is critical to avoiding irreversible neurological damage.



5. DIAGNOSIS

5.1 Neuroimaging

Neuroimaging often includes MRI especially for CNS diseases therefore it plays a crucial role in diagnostic process of PML. The classical MRI findings of PML lesions are multifocal, asymmetrical white matter lesions located primarily in the subcortical white matter of the

Prieto-occipital and frontal lobes. The lesions are hyper intense on T2-weighted and FLAIR MRI, and lack edema, mass effect, and/or significant enhancement (for example, no

significant enhancement when compared to the non-enhanced expected appearance), which can aid differentiation from tumors and abscesses. As PML lesions progress, the lesions can coalesce to manifest widespread demyelination.



A. Lesions in white matter
B. Normal Brain MRI

(Image is from research gate site)

5.2 Laboratory Testing

Detection of JC virus DNA in the cerebrospinal fluid (CSF) by PCR is essential in confirming laboratory diagnosis of PML. PCR can be highly specific to a diagnosis but may have limitations in early detection through false-negative reporting as the clinical picture evolves. A negative PCR result does not exclude PML, especially in the context of clinical and radiological signs or symptoms. In specific cases, even serial lumbar puncture or Quantitative Viral Load analysis could be useful in detection of JC virus in CSF. As for JC virus in the blood, IgG status testing may be useful to assess pre-existing risk factors for acquiring PML in patients prior to beginning immunosuppression with immunomodulating agents.

5.3 Brain Biopsy

Brain biopsy is left for ambiguous cases, but is the gold standard when noninvasive approaches fail. Histopathology would show areas of demyelination, enlarged oligodendrocytes with viral correlates, atypical astrocytes with bizarre nuclei, and other histologic abnormalities. Immunohistochemical stains may identify JC viral proteins.

5.4 Differential Diagnosis

Differentials include multiple sclerosis, CNS lymphoma, HIV-associated neurocognitive disorder, cytomegalovirus encephalitis, and drug induced leukoencephalopathy. Each disorder has distinguishing factors, including pattern of lesions, behavior of enhancement, and appreciation for response to immunotherapy.

Table 2: Diagnostic Criteria for PML (Adapted from Berger et al., 2013)

Criterion	Diagnostic Requirement
Clinical Presentation	Gradually progressive neurological impairments (e.g., weakness, vision loss, cognitive decline).
Neuroimaging (MRI)	Presence of multifocal, asymmetric white matter lesions with no mass effect or enhancement.
Virological Evidence	Detection of JC virus DNA in cerebrospinal fluid by PCR, or confirmation through brain biopsy.

6. TREATMENT AND MANAGEMENT

6.1 Immune Reconstitution

The key strategy for management of PML is restoration of immune function, which is the best hope for halting progression of the disease. In HIV-infected individuals, starting or fully optimizing antiretroviral therapy (ART) is an effective approach for reducing the JC virus replication, and improving outcomes. In non-HIV patients, such as those receiving all immunosuppressive or immunomodulatory drugs (e.g.: natalizumab, rituximab, fingolimod), the strategy is to either rapidly stop the immunosuppressant, or reduce the dose of the therapy. In some of these patients, plasma exchange (PLEX) is used to remove medications, like natalizumab, very quickly. Ultimately, the reconstitution of immune function must be managed carefully to avoid immune reconstitution inflammatory syndrome (IRIS), which can paradoxically worsen outcomes due to inflammation itself.

6.2 Antiviral and Adjunctive Therapies

Currently, antiviral agents targeting JC virus do not have consistent efficacy in treating or preventing JC. Trials of immune checkpoint inhibitors (such as pembrolizumab) and adoptive transfer of JC virus-specific T-cells, promoting antiviral immune response in the patient, have been undertaken. Other agents under investigation include mirtazapine, which may inhibit entry of JC virus into glial cells, and interleukin-7, which enhances T-cell function. All of these agents are investigational and, Such treatments are

currently considered experimental and are reserved for cases where immune restoration fails.

6.3 Supportive Care

A comprehensive supportive care regimen will enhance quality of life. This will include neurological rehabilitation, occupational therapy, speech therapy, and psychological counseling. Treating secondary complications and symptoms like seizures, infections, and mobility will hopefully minimize complications otherwise cascading into further decline. Comfort care can be provided as a form of help and support to individuals facing serious illnesses, either during the end of life to enhance their dignity and comfort or at any stage to improve their quality of life.

7. PREVENTION AND MONITORING

7.1 Risk Assessment

The number one way to prevent PML is by effectively carrying out risk stratification Ideally, risk stratification should be performed prior to the initiation of immunomodulatory therapy (e.g., natalizumab, fingolimod, etc.) (say, before the patient begins their treatment with rituximab). Bloomgren et al. (2012) advocate checking all patients for anti-JC virus antibodies, which will identify a patient with latent infection and determine the risk of a future reactivation. Individuals with anti-JC virus antibodies who have received extended exposure to such drug therapies (or have ever had previous treatment with any form of immunosuppressant) have a significantly higher chance of developing PML. Risk stratification is used in order to assess treatment options and weigh the therapeutic benefits against neurological risks.

7.2 Surveillance

Continuous clinical monitoring and imaging is needed in patients on high-risk therapies. Ho & Tourbah (2014) suggest that a brain MRI every 3–6 months is ideal to catch abnormalities early on, even if asymptomatic. Neurological assessments are important to measure subtle cognitive, motor, vision, and speech changes. Early detection of concerning symptoms or suspicious radiological appearances enables initiating treatment. To reverse neurological disease can be achieved through immune recovery.

7.3 Patient Education

Providing patients with education is an essential component of PML prevention. (Tan & Koralnik (2010) noting that patients must be made aware of early signs and symptoms, such as unexplained weakness, changes in behavior, memory loss, and visual changes. Educating patients encourages self-reporting for new symptoms, and will reduce delays and missed diagnoses. Education also increases the likelihood that patients will follow through with appropriate surveillance practices, as well as share the earliest warning sign of neurological decline with their clinician.

8. PROGNOSIS

Progressive Multifocal Leukoencephalopathy (PML) is still associated with a guarded prognosis despite advances in treatment. One-year survival rates after diagnosis are generally between 30% and 50%, but early diagnosis and fast immune restoration are correlated with better neurological outcomes with some level of functional recovery.

Prognosis also depends on the nature of the cause of immunosuppression, the speed of immune restoration, and extent of Central Nervous System (CNS) involvement at the time of diagnosis. Patients who are diagnosed early when a response to antiretroviral therapy, as in the case of HIV, and quickly stop the immunosuppressive drug, are likely to experience an improved prognosis, although neurological deficits most likely would persist and ultimately alter their quality of life.

The most prominent issue during immune restoration is Immune Reconstitution Inflammatory Syndrome (IRIS), which is an inflammatory response to an increase in immune function, resulting paradoxically in clinical deterioration of neurological symptoms. In the extreme short-term, IRIS may worsen neurological function, but to confusion, it may also mean immune recovery and management can lead to clinical stabilization or partial recovery from damage due to PML.

While the future remains promising through ongoing clinical trials and immunotherapeutics against this disorder, until good antiviral options emerge, early diagnosis, risk stratification, and prompt treatment when prescribed remains the most useful prognostics.

9. FUTURE DIRECTIONS

There are many possible research directions to improve this devastating disease as PML research is an evolving field. Current therapies target immune reconstitution and not viral clearance. Consequently, researchers are pursuing a combination of interventions to improve results.

- Antiviral Agents: There is a consensus that finding direct-acting antiviral agents against the JC virus remains a high priority. Compounds being studied include entry inhibitors and agents that target viral replication, but none of the compounds have demonstrated sufficient clinical activity (reliable and reproducible clinical efficacy). Ideally, research will lead to a targeted antiviral agent for patients not candidates for immune reconstitution.
- Biomarkers: Research efforts are underway to detect biomarkers that could predict JC virus reactivation and early phases of demyelination. Biomarkers would permit intervention by clinicians before irreversible brain damage occurs.
- Immunotherapy: Further, several studies are underway for immune checkpoint inhibitors (e.g., pembrolizumab) and JC virus-specific T-cell therapy as a method to restore antiviral immunity while not driving excessive inflammation. The

ultimate goal is to develop a therapeutic strategy that facilitates viral clearance while not leading to immune-related damage.

10. CONCLUSION

Progressive Multifocal Leukoencephalopathy (PML) is a rare, opportunistic demyelinating disease of the CNS resulting from reactivation of JC virus in immunocompromised individuals. While PML was once more commonly associated with the AIDS epidemic, it is increasingly being seen in patients receiving long-term immunosuppressive or immunomodulatory therapies. Overall the most effective management approaches are diagnosing early, stopping concerned medications, and restoring vigorous immune function. There are no specific antiviral treatment for JC virus reactivation related to PML, but trial work in targeted therapy, immune based therapy, and predictive biomarkers continues to provide hope for those afflicted by this disease. Raising awareness and vigilance is important for clinicians to facilitate improved outcomes and reduce the chronic burden of the often devastating long-term complications of PML.

11. CASE STUDY

Case Scenario: PML in a Patient with Hematological Malignancy in India

A 68-year-old male from a metropolitan city in India, with a known history of chronic lymphocytic leukemia (CLL) for which he had been receiving chemotherapy and rituximab (a monoclonal antibody) for the past two years, began experiencing new neurological symptoms.

Over a period of approximately three weeks, his family noticed a progressive decline in his cognitive abilities, including increasing confusion, difficulty concentrating, and impaired short-term memory. He also developed a subtle weakness in his left arm and leg, which gradually worsened, affecting his ability to walk independently. There were no signs of fever, headache, or other systemic infections.

Upon admission, a neurological examination revealed a right-sided hemiparesis, mild ataxia, and significant global cognitive impairment. His general physical examination was consistent with his underlying CLL and the effects of chemotherapy, but no other acute issues were noted.

Brain MRI was performed, which showed multiple, asymmetric, non-enhancing T2-weighted and FLAIR hyperintense lesions scattered throughout the white matter of the right cerebral hemisphere, particularly in the subcortical and periventricular regions. These lesions did not show any mass effect or surrounding edema.

Cerebrospinal fluid (CSF) analysis was conducted, and the PCR test for JC virus DNA returned positive, confirming the diagnosis of PML. Routine CSF parameters were largely normal, helping to rule out other infectious or inflammatory conditions.

Given the diagnosis of PML in the context of his immunosuppression due to CLL and its treatment, the patient's rituximab therapy was discontinued. Efforts were made to manage his underlying leukemia with alternative strategies, and supportive care, including physical and occupational therapy, was initiated to help with his neurological deficits.

Despite these interventions, the patient's neurological condition showed limited improvement, and he continued to experience significant cognitive and motor impairments, requiring ongoing care. This case highlights how PML can manifest in Indian patients with compromised immune systems due to conditions like hematological malignancies and the use of immunosuppressive therapies, even in the absence of HIV.

12. INFOGRAPHICS

This infographic shows the stepwise pathogenesis of PML in a pictorial format:

- **Latent Infection**: For most people, JC virus is latent in kidneys, bone marrow, or lymphoid tissues.
- **Immune Suppression:** The immune system's ability to surveil is compromised through HIV/AIDS, immunosuppressive therapy (e.g. natalizumab), or organ-transplantation.
- **Reactivation and Neuroinvasion:** Reactivated JC virus has entered the CNS after surfacing the blood-brain barrier.
- **Infection of Glial Cells:** The virus infects oligodendrocytes, which produce myelin, leading to cell death.
- **Demyelination:** Loss of myelin creates the classical multifocal lesions in white matter with accompanying neurological deficits.

13. BREAKING DOWN PML: FROM RISK TO RECOVERY

Q1: Is PML contagious?

No. PML is caused by reactivation of the JC virus already latent in the body and is not contagious (Du Pasquier & Koralnik, 2013).

Q2: Can PML be cured?

There is no cure, but early immune restoration can stabilize or improve symptoms (Tan & Koralnik, 2010).

Q3: Who is most at risk?

Immunocompromised individuals, especially HIV patients without ART and those on immunomodulatory drugs (Berger et al., 2013).

Q4: How is PML diagnosed?

MRI and JC virus PCR in CSF are key tools; biopsy if uncertain (Berger et al., 2013).

Q5: Can immunosuppressive drugs be safely used?

They must be carefully monitored; risk-benefit balance is essential, and screening for JC virus antibodies is recommended (Bloomgren et al., 2012).

14. MYTHS VS FACTS: CLEARING THE CONFUSION AROUND PML

Myth	Fact
PML only affects people with HIV/AIDS.	PML can develop in **any individual with severe immunosuppression**, including those on immunomodulatory or chemotherapy agents. *(Koralnik & Tyler, 2016)*
Everyone with JC virus infection will develop PML.	While **JC virus is widespread**, PML only occurs in a **small subset of people** with significant immune dysfunction. *(Du Pasquier & Koralnik, 2013)*
PML is a curable condition.	There is **no direct cure**, but therapies that **restore immune function**—such as discontinuation of immunosuppressants or initiation of ART—can slow or halt disease progression. *(Cortese, Reich & Nath, 2021)*
PML is contagious.	PML is **not infectious**. It arises from **reactivation of latent JC virus** within the host under immunocompromised conditions. *(Tan & Koralnik, 2010)*

REFERENCES

- **Abstract**
  - Du Pasquier RA, & Koralnik IJ. (2013). *JC virus infection in the central nervous system*. Clinical and Developmental Immunology, 2013:373579.
  - Tan CS, & Koralnik IJ. (2010). *Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis*. The Lancet Neurology, 9(4), 425–437.
  - White MK, & Khalili K. (2011). *Pathogenesis of progressive multifocal leukoencephalopathy: a molecular update*. FEBS Journal, 278(22), 4116–4126.

1. Introduction

  - Du Pasquier RA, & Koralnik IJ. (2013). *JC virus infection in the central nervous system*. Clinical and Developmental Immunology, 2013:373579.
  - Koralnik IJ. (2006). *Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?* Annals of Neurology, 60(2), 162–173.
  - White MK, & Khalili K. (2011). *Pathogenesis of progressive multifocal leukoencephalopathy: a molecular update*. FEBS Journal, 278(22), 4116–4126.
  - Tan CS, & Koralnik IJ. (2010). *Progressive multifocal leukoencephalopathy and other disorders caused by JC virus*. The Lancet Neurology, 9(4), 425–437.

2. Etiology and Pathogenesis

  - Du Pasquier RA, & Koralnik IJ. (2013). *JC virus infection in the central nervous system*. Clinical and Developmental Immunology, 2013:373579.
  - Tan CS, & Koralnik IJ. (2010). *Progressive multifocal leukoencephalopathy and other disorders caused by JC virus*. The Lancet Neurology, 9(4), 425–437.
  - Hoang-Xuan K, Delattre JY, Assan R, et al. (1986). *Progressive multifocal leukoencephalopathy in AIDS: clinical and neuropathological features*. Journal of Neurology, Neurosurgery & Psychiatry, 49(11), 1324–1330.
  - Major EO, Amemiya K, Tornatore CS, et al. (1992). *Biology of JC virus and progressive multifocal leukoencephalopathy*. Annals of Neurology, 31(5), 503–511.
  - Wüthrich C, Montrasio F, Sawa M, et al. (2012). *Progressive multifocal leukoencephalopathy in patients with immune-mediated diseases*. Neurology, 79(14), 1445–1451.
  - Tan CS, Ellis LC, Sejvar JJ, et al. (2013). *The effect of natalizumab on JC virus serology and incidence of PML in multiple sclerosis patients*. Neurology, 81(6), 512–518.
  - Bloomgren G, Richman S, Hotermans C, et al. (2012). *Risk of natalizumab-associated progressive multifocal leukoencephalopathy*. New England Journal of Medicine, 366(20), 1870–1880.
  - Clifford DB, Ances BM, Costello C, et al. (2011). *Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis*. Archives of Neurology, 68(9), 1156–1164.
  - Richardson EP Jr, & Berger JR. (1998). *Progressive multifocal leukoencephalopathy and human immunodeficiency virus infection*. Journal of NeuroVirology, 4(1), 45–57.
  - D'Arcy S, Galvin A, Coffey E, et al. (2015). *JC virus infection in congenital immunodeficiency: a rare cause of PML*. Journal of Clinical Virology, 68, 62–64.

3. Epidemiology

- Koralnik IJ, & Tyler KL. (2016). *Progressive multifocal leukoencephalopathy: current insights*. Nature Reviews Neurology, 12(4), 211–222.
- Berger JR, & Houff S. (2006). *Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab*. Neurologic Clinics, 24(3), 547–567.
- Ho D, & Tourbah A. (2014). *Progress in diagnosis and management of PML in multiple sclerosis*. Journal of Neurology, Neurosurgery & Psychiatry, 85(10), 1157–1163.

4. Clinical Presentation

- Tan CS, & Koralnik IJ. (2010). *Progressive multifocal leukoencephalopathy and other disorders caused by JC virus*. The Lancet Neurology, 9(4), 425–437.
- Koralnik IJ, & Wüthrich C. (2007). *Visual manifestations of JC virus infection in the CNS*. Neurology, 68(1), 36–38.
- Marzocchetti A, Tompkins T, Clifford DB, et al. (2009). *Cognitive impairment and survival in PML patients*. Neurology, 72(5), 431–436.
- Cinque P, Koralnik IJ, & Clifford DB. (2003). *Progressive multifocal leukoencephalopathy in HIV infection: pathogenesis and treatment*. The Lancet Infectious Diseases, 3(12), 795–803.
- Cortese I, Reich DS, & Nath A. (2021). *Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease*. Nature Reviews Neurology, 17(1), 37–51.
- Berger JR, Aksamit AJ, Clifford DB, et al. (2013). *PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section*. Neurology, 80(15), 1430–1438.

5. Diagnosis

- Berger JR, Aksamit AJ, Clifford DB, et al. (2013). *PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section*. Neurology, 80(15), 1430–1438.
- Tan CS, & Koralnik IJ. (2010). *Progressive multifocal leukoencephalopathy and other disorders caused by JC virus*. The Lancet Neurology, 9(4), 425–437.

6. Treatment and Management

- Tan CS, & Koralnik IJ. (2018). *Novel immunotherapies and PML: balance between efficacy and safety*. Neurology, 90(4), 163–170.
- Cortese I, Reich DS, & Nath A. (2021). *Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease*. Nature Reviews Neurology, 17(1), 37–51.

7. Prevention and Monitoring

- Bloomgren G, Richman S, Hotermans C, et al. (2012). *Risk of natalizumab-associated progressive multifocal leukoencephalopathy*. New England Journal of Medicine, 366(20), 1870–1880.
- Ho D, & Tourbah A. (2014). *Progress in diagnosis and management of PML in multiple sclerosis*. Journal of Neurology, Neurosurgery & Psychiatry, 85(10), 1157–1163.
- Tan CS, & Koralnik IJ. (2010). *Progressive multifocal leukoencephalopathy and other disorders caused by JC virus*. The Lancet Neurology, 9(4), 425–437.

8. Prognosis

- Berger JR, Aksamit AJ, Clifford DB, et al. (2013). *PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section*. Neurology, 80(15), 1430–1438.
- Tan CS, & Koralnik IJ. (2018). *Progressive multifocal leukoencephalopathy: current treatment options and future directions*. Therapeutic Advances in Neurological Disorders, 11, 1–15.

9. Future Directions

- Tan CS, & Koralnik IJ. (2018). *Progressive multifocal leukoencephalopathy: current treatment options and future directions*. Therapeutic Advances in Neurological Disorders, 11, 1–15.
- Cortese I, Reich DS, & Nath A. (2021). *Progressive multifocal leukoencephalopathy and the spectrum of JC virus–related disease*. Nature Reviews Neurology, 17(1), 37–51.

13. Breaking Down PML (Q&A)

- Du Pasquier RA, & Koralnik IJ. (2013). *JC virus infection in the central nervous system*. Clinical and Developmental Immunology, 2013:373579.
- Tan CS, & Koralnik IJ. (2010). *Progressive multifocal leukoencephalopathy and other disorders caused by JC virus*. The Lancet Neurology, 9(4), 425–437.
- Berger JR, Aksamit AJ, Clifford DB, et al. (2013). *PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section*. Neurology, 80(15), 1430–1438.
- Bloomgren G, Richman S, Hotermans C, et al. (2012). *Risk of natalizumab-associated progressive multifocal leukoencephalopathy*. New England Journal of Medicine, 366(20), 1870–1880.

14. Myths vs Facts

- Koralnik IJ, & Tyler KL. (2016). *Progressive multifocal leukoencephalopathy: current insights*. Nature Reviews Neurology, 12(4), 211–222.

- Du Pasquier RA, & Koralnik IJ. (2013). *JC virus infection in the central nervous system*. Clinical and Developmental Immunology, 2013:373579.
- Cortese I, Reich DS, & Nath A. (2021). *Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease*. Nature Reviews Neurology, 17(1), 37–51.
- Tan CS, & Koralnik IJ. (2010). *Progressive multifocal leukoencephalopathy and other disorders caused by JC virus*. The Lancet Neurology, 9(4), 425–437.